| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $625,431 | 44 | 100 |
| Schacterle Amy | Chief Regulatory Officer | 0 | $0 | 1 | $2,176 | $-2,176 |
| Fountain Nathan B | director | 0 | $0 | 1 | $14,273 | $-14,273 |
| Doherty James J. | President and CDO | 0 | $0 | 2 | $15,148 | $-15,148 |
| Siemers Eric | Chief Medical Officer | 0 | $0 | 4 | $27,110 | $-27,110 |
| Barton Russell | Chief Operating Officer | 0 | $0 | 6 | $29,917 | $-29,917 |
| Zuga Matt | CFO & Chief Business Officer | 0 | $0 | 6 | $49,556 | $-49,556 |
| Porter Derrell | director | 0 | $0 | 3 | $75,240 | $-75,240 |
| OConnell Daniel Joseph | Chief Executive Officer | 0 | $0 | 8 | $163,123 | $-163,123 |
| Meisner Derek M | Chief Legal Officer & Corp Sec | 0 | $0 | 13 | $248,888 | $-248,888 |
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its …
Over the last 12 months, insiders at Acumen Pharmaceuticals, Inc. have bought $0 and sold $625,431 worth of Acumen Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Acumen Pharmaceuticals, Inc. have bought $40M and sold $319,607 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,161,290 shares for transaction amount of $40M was made by RA CAPITAL MANAGEMENT, L.P. () on 2023‑07‑21.
| 2026-06-17 | Sale | Porter Derrell | director | 13,040 0.0219% | $2.33 | $30,318 | +2.67% | |
| 2026-06-16 | Sale | Porter Derrell | director | 12,800 0.0215% | $2.33 | $29,773 | +0.87% | |
| 2026-06-15 | Sale | Porter Derrell | director | 6,460 0.0107% | $2.35 | $15,149 | -1.50% | |
| 2026-06-09 | Sale | Fountain Nathan B | director | 6,400 0.0108% | $2.23 | $14,273 | +5.48% | |
| 2026-03-06 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 2,090 0.0034% | $3.26 | $6,813 | -25.08% | |
| 2026-02-27 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 9,406 0.0149% | $3.01 | $28,311 | -20.70% | |
| 2026-01-28 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 2,671 0.0049% | $3.00 | $8,017 | -10.68% | |
| 2026-01-26 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 15,085 0.0359% | $3.00 | $45,263 | +20.67% | |
| 2026-01-23 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 5,633 0.0089% | $1.90 | $10,718 | +26.77% | |
| 2026-01-22 | Sale | OConnell Daniel Joseph | Chief Executive Officer | 2,689 0.0042% | $1.88 | $5,066 | +26.13% | |
| 2026-01-22 | Sale | Zuga Matt | CFO & Chief Business Officer | 1,687 0.0026% | $1.86 | $3,138 | +26.13% | |
| 2026-01-22 | Sale | Siemers Eric | Chief Medical Officer | 895 0.0014% | $1.82 | $1,629 | +26.13% | |
| 2026-01-22 | Sale | Barton Russell | Chief Operating Officer | 462 0.0007% | $1.84 | $850 | +26.13% | |
| 2026-01-22 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 1,054 0.0016% | $1.84 | $1,939 | +26.13% | |
| 2026-01-21 | Sale | OConnell Daniel Joseph | Chief Executive Officer | 9,346 0.0154% | $1.81 | $16,927 | +38.67% | |
| 2026-01-21 | Sale | Zuga Matt | CFO & Chief Business Officer | 2,473 0.0041% | $1.81 | $4,469 | +38.67% | |
| 2026-01-21 | Sale | Siemers Eric | Chief Medical Officer | 2,331 0.0038% | $1.80 | $4,204 | +38.67% | |
| 2026-01-21 | Sale | Barton Russell | Chief Operating Officer | 2,315 0.0038% | $1.81 | $4,181 | +38.67% | |
| 2026-01-21 | Sale | Meisner Derek M | Chief Legal Officer & Corp Sec | 2,247 0.0037% | $1.81 | $4,063 | +38.67% | |
| 2026-01-12 | Sale | OConnell Daniel Joseph | Chief Executive Officer | 5,388 0.0089% | $1.73 | $9,307 | +44.77% |
| Fountain Nathan B | director | 48150 0.0666% | $11,286.36 | 1 | 1 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 13043179 18.0335% | $3.06M | 2 | 0 | <0.0001% | |
| Hardie Robert D. | 10 percent owner | 3951156 5.4629% | $926,150.97 | 1 | 0 | <0.0001% |
| Sands Capital Ventures Discovery Fund III, L.P. | 10 percent owner | 3417075 4.7245% | $800,962.38 | 1 | 0 | <0.0001% |
| Manning Paul B | 10 percent owner | 3352693 4.6354% | $785,871.24 | 1 | 0 | <0.0001% |
| Stalfort John A III | director | 172324 0.2383% | $40,392.75 | 1 | 0 | <0.0001% |
$18,815,063 | 62 | -6.45% | $13.7M | |
$1,993,425 | 46 | -21.91% | $13.95M | |
$226,127 | 22 | -27.62% | $21.96M | |
$37,200,153 | 21 | -47.67% | $12.66M | |
$114,619,342 | 20 | -7.41% | $16.39M |
| Increased Positions | 26 | +30.23% | 629,448 | +1.76% |
| Decreased Positions | 31 | -36.05% | 643,693 | -1.8% |
| New Positions | 13 | New | 297,665 | New |
| Sold Out Positions | 8 | Sold Out | 84,966 | Sold Out |
| Total Postitions | 81 | -5.81% | 36M | -0.04% |
| Ra Capital Management, L.P. | $30,163.00 | 24.48% | 14.93M | 0 | 0% | 2025-09-30 |
| Sands Capital Alternatives, Llc | $6,902.00 | 5.6% | 3.42M | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $4,656.00 | 3.78% | 2.31M | -771,943 | -25.09% | 2025-09-30 |
| Fmr Llc | $4,099.00 | 3.33% | 2.03M | -411 | -0.02% | 2025-09-30 |
| Vanguard Group Inc | $3,336.00 | 2.71% | 1.65M | -37,879 | -2.24% | 2025-09-30 |
| Knollwood Investment Advisory, Llc | $3,290.00 | 2.67% | 1.63M | 0 | 0% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $1,898.00 | 1.54% | 939,603 | 0 | 0% | 2025-09-30 |
| Adar1 Capital Management, Llc | $1,800.00 | 1.46% | 891,183 | -25,000 | -2.73% | 2025-09-30 |
| Laurion Capital Management Lp | $1,751.00 | 1.42% | 867,046 | 0 | 0% | 2025-09-30 |
| Pathstone Holdings, Llc | $1,735.00 | 1.41% | 859,110 | -199,421 | -18.84% | 2025-09-30 |